Oxford, UK – 7 June 2012. Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, will host a workshop at this year’s European Society of Human Genetics (ESHG) conference in Nürnberg, Germany (June 23-26). The session, entitled “Utilising arrays and next generation sequencing (NGS) to identify causative mutations in cancer and rare disease samples”, will take place on Saturday 23rd June between 11:45 and 13.15 in the Istanbul Room, where lunch will be provided. It will feature presentations from international experts in array and sequencing-based cancer and rare disease research, including a talk by Professor Jacqueline Schoumans, head of the Cancer Cytogenetic Unit in Lausanne University Hospital, Switzerland. Professor Schoumans has recently worked with OGT to successfully develop and design a new array combining copy number and single nucleotide polymorphism (SNP) probes for investigating genomic variation in a wide range of haematological and solid cancers.
Also talking at the workshop will be Dr Dan Swan, a Senior NGS Computational Biologist at OGT, who will be discussing how OGT’s Genefficiency Targeted Sequencing Service and bioinformatics expertise has allowed customers to successfully identify the genetic causes of cancer and rare disease. Utilising collaborative data, Dr Swan will provide a detailed review of OGT’s NGS analysis pipeline, which allows the rapid interpretation of vast NGS datasets into meaningful results. Specific topics covered will include the analysis of paired tumour/normal samples, the detection of copy number variants and loss of heterozygosity mapping. To register for OGT’s workshop, visit www.ogt.co.uk/ESHG2012.
OGT will also host a booth at ESHG 2012 (number 234), where the company’s experts will be on hand to discuss the needs of your cancer and rare disease studies. OGT offers a wide range of solutions, including its Genefficiency™ Genomic Services for enabling high-throughput, high-quality array and targeted sequencing studies, as well as its CytoSure™ range of products and services for cytogeneticists.
For more details, or to register for the workshop, please visit www.ogt.co.uk/ESHG2012.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, UK
T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: contact@ogt.co.uk
W: www.ogt.co.uk ; Twitter: @OxfordGeneTech
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.
Biomarker Discovery: OGT delivers tailored biomarker discovery solutions that optimise drug and diagnostic development programmes. With expertise in genomic and proteomic diagnostic biomarkers, OGT provides highly specific customised biomarker panels for cancer and other diseases, both for direct sale and also for collaboration with partner companies. Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high-quality genomic data to customers worldwide. OGT’s CytoSure™ cytogenetics array, labelling and interpretation software products and services provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.
CytoSure™: For research use only
This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.
